Latest Findings on COVID-19: BA.2.86 Strain Global Outbreak and Long COVID Impact – Insights from Assoc. Prof. Dr. Teera Worathanarat at Chulalongkorn University

2023-11-02 06:52:00

Assoc. Prof. Dr. Teera Worathanarat, Faculty of Medicine Chulalongkorn University Facebook post Thira Woratanarat stated Quick bites on COVID-19

1. BA.2.86 is likely to cause a global outbreak.

The Swedish team published the results of the study in the New England Journal of Medicine on October 26.

pointed out that Among people who have received a booster vaccine before or a group of people who have been infected with COVID-19 The previous species came first. This is despite the presence of detectable levels of immunity in the blood and in the respiratory mucosa. can still be infected with COVID-19 strain BA.2.86

This, together with what we know from basic knowledge found from previous research around the world, is that the BA.2.86 strain has many mutations in various positions, giving it a high ability to evade immunity.

Study from Sweden above Therefore, it emphasizes the importance of protective behavior during daily life.

2. Long COVID

A team from China reviewed the academic knowledge on Long COVID to date in the journal Signal Transduction and Targeted Therapy on November 1, 2023.

In summary, it is evident that the Long COVID problem has affected the quality of life of many people around the world. The pathomechanism has been studied. It has been found to be caused by the retention of viruses or virus fragments in the body, the ongoing inflammatory process, abnormal functioning of endothelial cells, the development of autoimmunity, and/or the loss of balance of Microorganisms in the body

The above mechanisms result in various abnormalities. followed in the long term Whether it’s the cardiovascular system respiratory system digestive system, nervous system, or reproductive system

Related Articles:  COVID-19 vs. Influenza: BA.2.86.x Strain Dominating Global Outbreak

Currently, research is being conducted to study ways to treat various disorders. Those in Long COVID patients, which will require further follow-up.

refer
1. Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection. NEJM. 26 October 2023.
2. The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Signal Transduction and Targeted Therapy. 1 November 2023.

1698972943
#Doctor #Teera #reveals #BA.2.86 #global #outbreak

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.